JPMorgan Chase & Co. Issues Pessimistic Forecast for Repligen (NASDAQ:RGEN) Stock Price

Repligen (NASDAQ:RGEN) had its price objective decreased by equities researchers at JPMorgan Chase & Co. from $180.00 to $165.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 30.51% from the stock’s previous close.

Several other research firms have also recently issued reports on RGEN. Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a report on Saturday, February 28th. Canaccord Genuity Group lowered their price objective on Repligen from $165.00 to $145.00 and set a “hold” rating on the stock in a report on Monday, April 20th. KeyCorp reiterated an “overweight” rating on shares of Repligen in a report on Wednesday, February 25th. Roth Mkm began coverage on Repligen in a report on Friday, April 17th. They set a “buy” rating and a $160.00 target price on the stock. Finally, Barclays boosted their target price on Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Repligen has an average rating of “Moderate Buy” and a consensus price target of $169.62.

Repligen Trading Up 0.5%

RGEN stock opened at $126.43 on Wednesday. The company has a current ratio of 9.20, a quick ratio of 7.12 and a debt-to-equity ratio of 0.26. Repligen has a 12-month low of $109.50 and a 12-month high of $175.77. The stock has a market cap of $7.13 billion, a price-to-earnings ratio of 140.48, a PEG ratio of 2.42 and a beta of 1.09. The business’s 50-day moving average is $121.00 and its 200 day moving average is $144.12.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The company had revenue of $194.26 million for the quarter, compared to analysts’ expectations of $192.05 million. During the same period in the previous year, the firm posted $0.39 EPS. Repligen’s revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, sell-side analysts anticipate that Repligen will post 1.99 EPS for the current fiscal year.

Institutional Trading of Repligen

Several institutional investors have recently made changes to their positions in RGEN. Dimensional Fund Advisors LP raised its position in Repligen by 6.3% in the first quarter. Dimensional Fund Advisors LP now owns 854,741 shares of the biotechnology company’s stock valued at $100,681,000 after purchasing an additional 50,331 shares during the period. KBC Group NV raised its position in Repligen by 20.7% in the first quarter. KBC Group NV now owns 1,837 shares of the biotechnology company’s stock valued at $216,000 after purchasing an additional 315 shares during the period. Swiss National Bank raised its position in Repligen by 0.4% in the first quarter. Swiss National Bank now owns 105,800 shares of the biotechnology company’s stock valued at $12,465,000 after purchasing an additional 400 shares during the period. Roubaix Capital LLC purchased a new stake in Repligen in the first quarter valued at approximately $6,428,000. Finally, Angeles Wealth Management LLC raised its position in Repligen by 27.3% in the first quarter. Angeles Wealth Management LLC now owns 2,587 shares of the biotechnology company’s stock valued at $305,000 after purchasing an additional 555 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.